Filing Flows › Bio-Rad Laboratories (BIO) › Q3 2026 › vs Q2 2026
Bio-Rad Laboratories (BIO) Q3 2026 vs Q2 2026 (quarter over quarter)
Bio-Rad Laboratories's revenue rose $5.4M (+0.8%) from $651M in Q2 2026 to $656M in Q3 2026. The biggest changes: Clinical Diagnostics +$2.8M (+0.7%); Life Science +$2.6M (+1%).
Bio-Rad Laboratories, Q3 2026: revenue $656M (+0.5% year over year), operating margin -7.6%, net earnings $459M, operating cash flow $96.4M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 9.9% | 10.2% | -0.3 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Clinical Diagnostics | $402M | $399M | $2.8M | +0.7% |
| Life Science | $255M | $252M | $2.6M | +1% |
| Revenue | $656M | $651M | $5.4M | +0.8% |
| Other income, net | $588M | $470M | $119M | +25% |
| Costs & expenses | $1.2B | $1.1B | $124M | +11% |
| Operating costs | $706M | $578M | $128M | +22% |
| Income tax | $80.1M | $171M | −$90.6M | -53% |
| Net earnings | $459M | $371M | $87.2M | +23% |
| Cost of revenue | $328M | $305M | $22.6M | +7% |
| Research & development | $71.4M | $61.2M | $10.2M | +17% |
| SG&A | $257M | $212M | $45.1M | +21% |
| Operating cash sources | $474M | $386M | $88.2M | +23% |
| Share-based compensation | $15.5M | $14.5M | $1.0M | +7% |
| Working capital & other | $378M | $287M | $90.5M | +32% |
| Operating cash flow | $96.4M | $98.7M | −$2.3M | -2% |
| Free cash flow (OCF − capex) | $65.2M | $66.7M | −$1.5M | -2% |
| Capital expenditures | $31.2M | $32.0M | −$800K | -3% |
Questions
How much did Bio-Rad Laboratories's revenue grow quarter over quarter in Q3 2026?
Bio-Rad Laboratories's revenue rose $5.4M (+0.8%) from $651M in Q2 2026 to $656M in Q3 2026.
What drove Bio-Rad Laboratories's revenue change in Q3 2026?
Clinical Diagnostics +$2.8M (+0.7%); Life Science +$2.6M (+1%).